Literature DB >> 28456631

Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.

James K Y Hooi1, Wan Ying Lai1, Wee Khoon Ng2, Michael M Y Suen1, Fox E Underwood3, Divine Tanyingoh3, Peter Malfertheiner4, David Y Graham5, Vincent W S Wong1, Justin C Y Wu1, Francis K L Chan1, Joseph J Y Sung1, Gilaad G Kaplan6, Siew C Ng7.   

Abstract

BACKGROUND & AIMS: The epidemiology of Helicobacter pylori infection has changed with improvements in sanitation and methods of eradication. We performed a systematic review and meta-analysis to evaluate changes in the global prevalence of H pylori infection.
METHODS: We performed a systematic search of the MEDLINE and EMBASE databases for studies of the prevalence of H pylori infection published from January 1, 1970 through January 1, 2016. We analyzed data based on United Nations geoscheme regions and individual countries. We used a random effects model to calculate pooled prevalence estimates with 95% confidence intervals (CIs), weighted by study size. We extrapolated 2015 prevalence estimates to obtain the estimated number of individuals with H pylori infection.
RESULTS: Among 14,006 reports screened, we identified 263 full-text articles on the prevalence of H pylori infection; 184 were included in the final analysis, comprising data from 62 countries. Africa had the highest pooled prevalence of H pylori infection (70.1%; 95% CI, 62.6-77.7), whereas Oceania had the lowest prevalence (24.4%; 95% CI, 18.5-30.4). Among individual countries, the prevalence of H pylori infection varied from as low as 18.9% in Switzerland (95% CI, 13.1-24.7) to 87.7% in Nigeria (95% CI, 83.1-92.2). Based on regional prevalence estimates, there were approximately 4.4 billion individuals with H pylori infection worldwide in 2015.
CONCLUSIONS: In a systematic review and meta-analysis to assess the prevalence of H pylori infection worldwide, we observed large amounts of variation among regions-more than half the world's population is infected. These data can be used in development of customized strategies for the global eradication.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bacteria; Europe; Incidence; Stomach

Mesh:

Year:  2017        PMID: 28456631     DOI: 10.1053/j.gastro.2017.04.022

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  526 in total

Review 1.  Involvement of Helicobacter Pylori in Ocular Adnexa Lymphoma.

Authors:  Antonio Travaglino; Mirella Pace; Silvia Varricchio; Daniela Russo; Novella Pugliese; Alessandro Severino; Marco Picardi; Fabrizio Pane; Luigi Insabato; Stefania Staibano; Massimo Mascolo
Journal:  Pathol Oncol Res       Date:  2020-06-18       Impact factor: 3.201

2.  Cancer mortality rates among US and foreign-born individuals: United States 2005-2014.

Authors:  Benjamin D Hallowell; Meheret Endeshaw; Matthew T McKenna; Virginia Senkomago; Hilda Razzaghi; Mona Saraiya
Journal:  Prev Med       Date:  2019-06-18       Impact factor: 4.018

3.  α-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations in Helicobacter pylori cagY.

Authors:  Johanna C Sierra; Giovanni Suarez; M Blanca Piazuelo; Paula B Luis; Dara R Baker; Judith Romero-Gallo; Daniel P Barry; Claus Schneider; Douglas R Morgan; Richard M Peek; Alain P Gobert; Keith T Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-25       Impact factor: 11.205

4.  Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo.

Authors:  Jia Di; Jun Zhang; Lei Cao; Ting-Ting Huang; Jun-Xia Zhang; Yan-Ni Mi; Xue Xiao; Ping-Ping Yan; Man-Li Wu; Tong Yao; Dong-Zheng Liu; Jing Liu; Yong-Xiao Cao
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.

Authors:  Adam Tepler; Neeraj Narula; Richard M Peek; Anish Patel; Cyrus Edelson; Jean-Frederic Colombel; Shailja C Shah
Journal:  Aliment Pharmacol Ther       Date:  2019-06-05       Impact factor: 8.171

6.  Helicobacter pylori and Gallstone Disease: Incidence and Outcomes in a Los Angeles County Population.

Authors:  Sonam Kapadia; Amy H Kaji; Danielle M Hari; Junko Ozao-Choy; Kathryn T Chen
Journal:  J Gastrointest Surg       Date:  2021-02-23       Impact factor: 3.452

7.  Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.

Authors:  Shria Kumar; David C Metz; Gregory G Ginsberg; David E Kaplan; David S Goldberg
Journal:  Aliment Pharmacol Ther       Date:  2020-03-04       Impact factor: 8.171

8.  Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis.

Authors:  Baldeep S Pabla; Shailja C Shah; Juan E Corral; Douglas R Morgan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-30       Impact factor: 11.382

9.  VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1.

Authors:  Mariana I Capurro; Laura K Greenfield; Akriti Prashar; Sunny Xia; Majd Abdullah; Harikesh Wong; Xi Zoe Zhong; Nina Bertaux-Skeirik; Jayati Chakrabarti; Iram Siddiqui; Catherine O'Brien; Xianping Dong; Lisa Robinson; Richard M Peek; Dana J Philpott; Yana Zavros; Michael Helmrath; Nicola L Jones
Journal:  Nat Microbiol       Date:  2019-05-20       Impact factor: 17.745

10.  Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression.

Authors:  Jennifer M Noto; Kristie L Rose; Amanda J Hachey; Alberto G Delgado; Judith Romero-Gallo; Lydia E Wroblewski; Barbara G Schneider; Shailja C Shah; Timothy L Cover; Keith T Wilson; Dawn A Israel; Juan Carlos Roa; Kevin L Schey; Yana Zavros; M Blanca Piazuelo; Richard M Peek
Journal:  Mol Cell Proteomics       Date:  2018-11-19       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.